Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.42 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.41 |
| ▸ | MAPT | P10636 | 5/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4337426 | 0.83 | KDM4E (0.51) | KDM4EGAAALDH1A1HSD17B10MAPT | |
| SCHEMBL4340512 | 0.79 | KDM4E (0.65) | KDM4EGAAALDH1A1HSD17B10MAPT | |
| SCHEMBL4332758 | 0.79 | MEN1 (0.57) | KDM4EGAAALDH1A1HSD17B10MAPT | |
| SCHEMBL5480808 | 0.78 | KDM4E (0.40) | KDM4EGAAALDH1A1HSD17B10MAPT | |
| SCHEMBL4334694 | 0.78 | MEN1 (0.56) | KDM4EGAAALDH1A1HSD17B10MAPT | |
| Potassium SCHEMBL4334708 | 0.78 | MEN1 (0.56) | KDM4EGAAALDH1A1HSD17B10MAPT | |
| SCHEMBL5487624 | 0.78 | MAP2 (0.48) | KDM4EGAAALDH1A1HSD17B10MAPT | |
| Potassium Ion SCHEMBL4334700 | 0.77 | BUB1 (0.42) | KDM4EGAAALDH1A1HSD17B10MAPT | |
| SCHEMBL4332934 | 0.76 | KDM4E (0.52) | KDM4EGAAALDH1A1HSD17B10MAPT | |
| SCHEMBL13758135 | 0.76 | KDM4E (0.44) | KDM4EGAAALDH1A1HSD17B10MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7169925-B2 | Indole derivatives as interleukin-4 gene expression inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-01-30 | — | — | US | claimed |
| EP-1501796-A1 | 3-SUBSTITUTED AMINO-1H-INDOLE-2-CARBOXYLIC ACID AND 3-SUBSTITUTED AMINO-BENZO[B]THIOPHENE-2-CARBOXYLIC ACID DERIVATIVES AS INTERLEUKIN-4 GENE EXPRESSION INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2005-02-02 | — | — | EP | claimed |
| US-20040010029-A1 | Indole derivatives as interleukin -4 gene expression inhibitors | AVENTIS PHARMACEUTICALS INC. | 2004-01-15 | — | — | US | claimed |
| WO-2003091215-A1 | 3-SUBSTITUTED AMINO-1H-INDOLE-2-CARBOXYLIC ACID AND 3-SUBSTITUTED AMINO-BENZO’ B! THIOPHENE-2-CARBOXYLIC ACID DERIVATIVES AS INTERIEUKIN-4 GENE EXPRESSION INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2003-11-06 | — | — | WO | claimed |
| EP-1834947-A2 | 3-substituted amino-1H-indole-2-carboxylic acid and 3-substituted amino-benzo[B]thiophene-2carboxylic acid derivatives as interleukin-4 gene expression inhibitors | Aventis Pharmaceuticals, Inc. (US) | 2007-09-19 | — | — | EP | disclosed |
| EP-1501796-B1 | 3-(PYRIDINYL-AMINO)-1H-INDOLE-2-CARBOXYLIC ACID DERIVATIVES AS INTERLEUKIN-4 GENE EXPRESSION INHIBITORS | AVENTIS PHARMA INC (US) | 2007-05-09 | — | — | EP | disclosed |
| US-7169925-B2 | Indole derivatives as interleukin-4 gene expression inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-01-30 | — | — | US | disclosed |
| EP-1501796-A1 | 3-SUBSTITUTED AMINO-1H-INDOLE-2-CARBOXYLIC ACID AND 3-SUBSTITUTED AMINO-BENZO[B]THIOPHENE-2-CARBOXYLIC ACID DERIVATIVES AS INTERLEUKIN-4 GENE EXPRESSION INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2005-02-02 | — | — | EP | disclosed |
| US-20040010029-A1 | Indole derivatives as interleukin -4 gene expression inhibitors | AVENTIS PHARMACEUTICALS INC. | 2004-01-15 | — | — | US | disclosed |
| WO-2003091215-A1 | 3-SUBSTITUTED AMINO-1H-INDOLE-2-CARBOXYLIC ACID AND 3-SUBSTITUTED AMINO-BENZO’ B! THIOPHENE-2-CARBOXYLIC ACID DERIVATIVES AS INTERIEUKIN-4 GENE EXPRESSION INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040010029-A1 | Indole derivatives as interleukin -4 gene expression inhibitors | IL4, IL4I1, STAT4 | KDM4E 243/4885GAA 4448/4885ALDH1A1 1468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.